Sep. 24, 2014, 10:01 AM| Comment!
Sep. 24, 2014, 8:08 AM| Comment!
Jul. 9, 2013, 8:32 AMAcorda Therapeutics (ACOR) has acquired the rights in the Americas and certain other territories to two nerve pain treatments from NeurogesX (NGSX.OB) - FDA approved Qutenza and "Phase III ready" NP-1998. Acorda paid $8M up front and will pay as much as $5m in milestones related to NP-1998. (PR) | Comment!
ACOR vs. ETF Alternatives
Other News & PR